Home Carboxys myo-Inositol, hexa-3-pyridinecarboxylate

myo-Inositol, hexa-3-pyridinecarboxylate

CAS No.:
6556-11-2
Catalog Number:
AG01CBWK
Molecular Formula:
Molecular Weight:
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
Product Description
Catalog Number:
AG01CBWK
Chemical Name:
myo-Inositol, hexa-3-pyridinecarboxylate
CAS Number:
6556-11-2
MDL Number:
MFCD00006387
IUPAC Name:
[2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl] pyridine-3-carboxylate
InChI:
InChI=1S/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H
InChI Key:
MFZCIDXOLLEMOO-UHFFFAOYSA-N
EC Number:
229-485-9
UNII:
A99MK953KZ
Properties
Complexity:
1210  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
810.192g/mol
Formal Charge:
0
Heavy Atom Count:
60  
Hydrogen Bond Acceptor Count:
18  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
810.732g/mol
Monoisotopic Mass:
810.192g/mol
Rotatable Bond Count:
18  
Topological Polar Surface Area:
235A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.3  
Literature
Title Journal
Role of Niacin in Current Clinical Practice: A Systematic Review. The American journal of medicine 20170201
Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. Xenobiotica; the fate of foreign compounds in biological systems 20130901
Niacin: chemical forms, bioavailability, and health effects. Nutrition reviews 20120601
Synthesis and antihyperlipidemic activity of acetylated derivative of ulvan from Ulva pertusa. International journal of biological macromolecules 20120101
A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evidence-based complementary and alternative medicine : eCAM 20120101
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health technology assessment (Winchester, England) 20111201
Chinese herbal medicines for hypercholesterolemia. The Cochrane database of systematic reviews 20110706
Raynaud's phenomenon (primary). BMJ clinical evidence 20110101
Optimal management of peripheral arterial disease for the non-specialist. The Ulster medical journal 20110101
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. Healthcare informatics research 20101201
Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities. Bioorganic & medicinal chemistry 20100501
Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism. Lipids in health and disease 20100101
The mechanism and mitigation of niacin-induced flushing. International journal of clinical practice 20090901
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin. Vascular health and risk management 20081001
Mechanism of action of niacin. The American journal of cardiology 20080417
Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080215
Raynaud's phenomenon (primary). BMJ clinical evidence 20080101
Raynaud's phenomenon (secondary). BMJ clinical evidence 20080101
Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061101
High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia. Acta pharmacologica Sinica 20060601
Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese medicine 20060101
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). The American journal of cardiology 20050115
The nicotinic acid receptor--a new mechanism for an old drug. Lancet (London, England) 20040605
Purported benefits of inositol niacinate. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040201
Antihyperlipidemic effects of different molecular weight sulfated polysaccharides from Ulva pertusa (Chlorophyta). Pharmacological research 20031201
Niacin and cholesterol: role in cardiovascular disease (review). The Journal of nutritional biochemistry 20030601
Mechanism of action of niacin on lipoprotein metabolism. Current atherosclerosis reports 20000101
Enzymatic hydrolysis of pentaerythritoltetranicotinate and meso-inositolhexanicotinate in blood and tissues. Arzneimittel-Forschung 19790101
Purine nucleotide cycle. Evidence for the occurrence of the cycle in brain. The Journal of biological chemistry 19760125
Properties